KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Debt Ratio for 13 consecutive years, with 0.85 as the latest value for Q4 2025.

  • Quarterly Debt Ratio rose 16.27% to 0.85 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.85 through Dec 2025, up 16.27% year-over-year, with the annual reading at 0.85 for FY2025, 16.27% up from the prior year.
  • Debt Ratio for Q4 2025 was 0.85 at Halozyme Therapeutics, up from 0.68 in the prior quarter.
  • The five-year high for Debt Ratio was 0.88 in Q1 2023, with the low at 0.06 in Q2 2022.
  • Average Debt Ratio over 5 years is 0.61, with a median of 0.75 recorded in 2024.
  • The sharpest move saw Debt Ratio surged 1486.42% in 2021, then crashed 36.03% in 2022.
  • Over 5 years, Debt Ratio stood at 0.79 in 2021, then grew by 3.03% to 0.82 in 2022, then rose by 5.76% to 0.86 in 2023, then fell by 15.64% to 0.73 in 2024, then grew by 16.27% to 0.85 in 2025.
  • According to Business Quant data, Debt Ratio over the past three periods came in at 0.85, 0.68, and 0.73 for Q4 2025, Q3 2025, and Q2 2025 respectively.